Key Takeaway: Werewolf Therapeutics has announced its financial results for the fourth quarter and the full year of 2023. The report includes a business update that highlights the company's current operations and future outlook. This announcement may indicate positive growth and strategic direction for the company moving forward.
Price reaction · baseline $7.03 (2024-03-06 close) · hit pre-market · clean, no other HOWL news in the window
day 0 close · peak
-4%
Market Sentiment Analysis
POSITIVE FACTORS
Werewolf Therapeutics reported financial results for Q4 and full year 2023.
The company provided a business update, indicating ongoing operations.
The report may reflect growth and future potential.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
15%
average across 6 past catalysts
Lead asset
WTX-330
Phase 1 · Advanced or Metastatic Solid Tumors
Full Press Release Details
March 7, 2024
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)
Share this article:
facebook-icon
twitter-icon
linked-in-icon
Frequently Asked Questions
What financial results did Werewolf Therapeutics report?
Werewolf Therapeutics reported its financial results for Q4 and the full year 2023.
What updates were provided in the business report?
The report included a business update highlighting the company's current operations.